QGEN - Qiagen N.V.
| Previous close | 45.91 |
| Open | 45.86 |
| Bid | 45.96 x 1000 |
| Ask | 45.98 x 800 |
| Day's range | 45.78 - 46.01 |
| 52-week range | 40.38 - 51.18 |
| Volume | |
| Avg. volume | 838,223 |
| Market cap | 10.474B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 29.07 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio
Q1 2023: Net sales of $485 million (-23% at actual rates, -20% at constant exchange rates, CER); diluted EPS of $0.37 and adjusted diluted EPS of $0.51 // Net sales at CER of $502 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.47 CER // 12% CER sales growth in non-COVID product portfolio to $434 million, while COVID product sales decline 76% to $52 million // Full-year 2023 outlook reaffirmed for at least $2.05 billio
- GlobeNewswire
QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk
Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care physicians in populations at increased risk. The USPSTF issued a final report on May 2 to continue the “B” recommendation for screening of these populations, building on
- GlobeNewswire
QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
Japan to become the latest of more than 100 countries where QIAstat-Dx is available for molecular testing in diagnosing over 20 respiratory diseases from one patient sample // Generates actionable results in about one hour based on PCR technology, unique ability to provide Ct values and easy access to amplification curves to support clinical decisions // More than 3,500 QIAstat-Dx instruments installed worldwide at the end of 2022Venlo, the Netherlands, April 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN
- GlobeNewswire
QIAGEN announces expansion of Supervisory Board
Steve Rusckowski has joined Supervisory Board and will stand for election at Annual General Meeting in June 2023Venlo, the Netherlands, April 20, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a new member and will stand for election at the next Annual General Meeting schedu
- GlobeNewswire
QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023
Launch of cell-free DNA (cfDNA) next-generation sequencing kits to test liquid biopsies // Study to demonstrate QIAGEN’s expertise in detecting disease-relevant cfDNA mutations // New pan-cancer panels for digital PCR platform QIAcuity to be launched in fall 2023Venlo, the Netherlands, April 14, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other disease
- GlobeNewswire
QIAGEN’s QIAxcel Connect wins Red Dot design award
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive Red Dot award, highlights strategy of upgrading portfolio to add new features – in particular wireless connectivity // QIAxcel Connect offers scientists many benefits for nucleic acid analysis with minimal handling time, flexible throughput and speedVenlo, the Netherlands, March 29, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced tha
- GlobeNewswire
QIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)
SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissionsVenlo, The Netherlands, March 27, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals. The SBTi is a global body that enables companies to set ambitious emissions reductions target
- Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
- Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).
- Business Wire
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
VENLO, Netherlands, March 01, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.
- Business Wire
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
VENLO, The Netherlands, February 14, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the certification of QuantiFERON-TB Gold Plus (QFT-Plus) – the world’s leading tuberculosis (TB) blood test – under the European Union’s 2017/746 In Vitro Diagnostic Medical Devices Regulation (IVDR) which is replacing the 98/79/EC In Vitro Diagnostic Directive (IVDD). QFT-Plus is QIAGEN’s trusted test, endorsed by the WHO, that aids in indirect detection of the bacteria that causes
- Business Wire
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
VENLO, Netherlands, February 07, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2022.
- Business Wire
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
VENLO, The Netherlands, January 17, 2023--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing available for widescale use 18 months after being made available for research.
- Business Wire
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
VENLO, Netherlands, January 17, 2023--QIAGEN N.V. to release results for Q4 and Full-Year results 2022 and hold webcast
- Business Wire
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
VENLO, The Netherlands & SAN DIEGO, January 09, 2023--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the future of human identification (HID) and forensic investigation.
- Business Wire
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases
VENLO, Netherlands & SAN MATEO, Calif., January 05, 2023--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.
- Business Wire
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
GERMANTOWN, Md. & HILDEN, Germany, December 13, 2022--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen® KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic’s drug KRAZATI® (adagrasib) for non-small cell lung cancer (NSCLC).
- Business Wire
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
HILDEN, Germany & GERMANTOWN, Maryland, November 21, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the monkeypox (MPXV) test for its NeuMoDx automated PCR platform to strengthen surveillance and research into the current outbreak in non-endemic regions that has infected tens of thousands of people all over the world since first being identified in May 2022.
- Business Wire
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
VENLO, Netherlands, November 07, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter of 2022 and first nine months of 2022, and increased the outlook for full-year 2022.
- Business Wire
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
VENLO, Netherlands, October 21, 2022--QIAGEN N.V. to release results for Q3 2022 and hold Webcast
- Business Wire
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
HILDEN, Germany & GERMANTOWN, Md., September 15, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses. The new assays for the identification and quantification of the Epstein-Barr virus (EBV) and the human herpesvirus 6 (HHV-6) have received CE-IVD certification for the European Union and other countries that accept this marking.
- Business Wire
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
HILDEN, Germany & GERMANTOWN Md. & SOUTH SAN FRANCISCO, Calif., September 14, 2022--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.
- Business Wire
QIAGEN Issues 2021 Sustainability Report
VENLO, the Netherlands, August 18, 2022--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2021 Sustainability Report, outlining significant achievements in the areas of Environment, Social and Governance (ESG) as part of its strategy to become a stronger and more sustainable leader in providing Sample to Insight solutions that unlock valuable molecular insights for customers in the Life Science and Molecular Diagnostics industries.
- Business Wire
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
HILDEN, Germany & GERMANTOWN, Md,, August 15, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms.
- Business Wire
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
HILDEN, Germany & GERMANTOWN, Md., July 27, 2022--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers, particularly those involved in the biopharma industry:
